Similar articles

Abstract: Objective: This study was designed to detect the expression of bcl-2 and p53 proteins in colorectal carcinomas and to determine their association with the patient survival and stage of the diseases. Methods: Immunohistochemistry method was used to detect the expression of bcl-2 and p53 proteins in 93 cases of colorectal carcinoma. The stain results were obtained by analyzing the clinic-pathological characteristics of patients. Results: Fifty-seven percent (53/93) of the colorectal carcinomas were bcl-2 protein positive. The positive rate of bcl-2 protein in lymph node involvement cases was lower (15/37) than the cases without node involvement (38/58, P<0.01). The positive rate of p53 protein was 43% (40/93) in colon-rectum carcinomas. No significant correlation was observed between p53 protein expression and clinic-pathological manifestations (P>0.05) but the survival was significantly worse (P=0.0001) in the p53 protein positive cases. Neither bcl-2 nor p53 alone was correlated with stage of the disease. When combined bcl-2/p53 status was analyzed, a group with bcl-2(+) and p53(−) had the best prognosis. This group was significantly associated with earlier Dukes’ stages (P=0.1763). In multivariate Cox regression analysis, lymph node involvement and p53 protein expression were two independent factors correlated with survival time. Conclusion: The expression of bcl-2 and p53 represent biological characteristics of colorectal carcinomas. Assessment of both bcl-2 and p53 status may be valuable in predicting the prognosis of patients.

[1] Baretton, G.B., Diebold, J., Christoforis, G., Vogt, M., Muller, C., Dopfer, K., Schneiderbanger, K., Schmidt, M., Lohrs, U., 1996. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer, 77:255-264.

[2] Belluco, C., Guillem, J.G., Kemeny, N., Huang, Y., Klimstra, D., Berger, M.F., Cohen, A.M., 1996. p53 nuclear protein overexpression in colorectal cancer. A dominant predictor of survival in patients with advanced hepatic metastases. J. Clin. Oncol., 14:2696-2701.

[3] Bosari, S., Moneghini, L., Graziani, D., Lee, A.K., Murray, J.J., Coggi, G., Viale, G., 1995. bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum. Pathol., 26(5):534-540.

[4] Dix, B.R., Robbins, P., Soong, R., 1994. The common molecular genetic alterations in Dukes’ B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int. J. Cancer, 59(6):747-751.

[5] Flamini, G., Curiglian, G., Ratto, C., Astone, A., Ferretti, G., Nucera, P., Sofo, L., Sgambato, A., Boninsegna, A., Crucitti, F., Cittadini, A., 1996. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An Immunohistochemical Analysis Europ. J. Cancer, 32A:802-806.

[6] Flohil, C.C., Janssen, P.A., Bosman, F.T., 1996. Expression of bcl-2 protein in hyperplastic polyps, adenomas, and carcinomas of the colon. J. Pathol., 178:393-397.

[7] Garewal, H., Guillem, J.G., Klimstra, D.S., 1995. p53 nuclear overexpression may not be an independent prognostic marker in early colorectal cancer. Dis. Colon. Rectum., 38:1176-1181.

[8] Garewal, H., Bernstein, N., Bernstein, C., Sampliner, R., Payne, C., 1996. Reduced bile acid-induced apoptosis in “normal” colorectal mucosa: a potential biological marker for cancer risk. Cancer Res., 56(12):1480-1483.

[9] Gonzalez-Aguilera, J.J., Oliart, S., Azcoita, M.M., Fernandez-Peralta, A.M., 2004. Simultaneous mutations in K-ras and TP53 are indicative of poor prognosis in sporadic colorectal cancer. Am. J. Clin. Oncol., 27(1):39-45.

[10] Iacopetta, B., 2003. TP53 mutation in colorectal cancer. Hum. Mutat., 21(3):271-276.

[11] Kaklamanis, L., Savage, A., Mortensen, N., Tsiotos, P., Doussis-Anagnostopoulou, I., Biddolph, S., Whitehouse, R., Harris, A.L., Gatter, K.C., 1996. Early expression of bcl-2 protein in the adenoma–carcinoma sequence of colorectal neoplasia. J. Pathol., 179:10-14.

[12] Manne, U., Myers, R.B., Moran, C., Poczatek, R.B., Dillard, S., Weiss, H., Brown, D., Srivastava, S., Grizzle, W.E., 1997. Prognostic significance of bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int. J. Cancer, 74:346-358.

[13] Mosnier, J.F., Perret, A.G., Vindimian, M., Dumollard, J.M., Balique, J.G., Perpoint, B., Boucheron, S., 1996. An immunohistochemical study of the simultaneous expression of bcl-2 and p53 oncoproteins in epithelial tumor of the colon and rectum. Arch. Pathol. Lab. Med., 120(7):654.

[14] Myers, R.B., Lampejo, O., Herrera, G.A., 1995. TGF-alpha expression is a relatively late event in the progression of prostatic adenocarcinoma. J. Urol. Pathol., 3:195-204.

[15] Upadhyay, S., Li, G., Liu, H., 1995. bcl-2 suppresses expression of p21WAF/CIP1 in breast epithelial cells. Cancer Res., 55:4520-4524.

[16] Watson, N.F., Madjd, Z., Scrimegour, D., Spendlove, I., Ellis, I.O., Scholefield, J.H., Durrant, L.G., 2005. Evidence that the p53 negative/bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients. World J. Surg. Oncol., 3:47.

[17] Westra, J.L., Schaapveld, M., Hollema, H., de Boer, J.P., Kraak, M.M., de Jong, D., ter Elst, A., Mulder, N.H., Buys, C.H., Hofstra, R.M., Plukker, J.T., 2005. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J. Clin. Oncol., 23(24):5635-5643.